Myomo Boosts Revenue 21% on Referral Network Growth
Event summary
- Myomo reported $11.7M in Q2 2026 revenue, up 21% YoY, with 53% from recurring patient sources.
- Gross margin expanded by 940 basis points YoY to 72.1%, driven by higher ASP and cost reductions.
- Adjusted EBITDA loss improved by 79% YoY to $0.8M, with operating expenses held flat.
- Myomo raised full-year revenue guidance to $45M–$47M, up from prior expectations.
The big picture
Myomo's shift to a recurring patient model aligns with broader trends in medical device adoption, where clinician referrals and payer contracts drive sustained demand. The company's ability to expand gross margins while holding operating expenses flat suggests operational maturity, but scaling these efficiencies will be critical as it targets mid-teens revenue growth.
What we're watching
- Referral Network Scaling
- Whether Myomo can sustain the 53% revenue contribution from recurring patient sources.
- Payer Contract Expansion
- The pace at which additional payer contracts will broaden market access beyond the current 100M covered lives.
- Product Development Timing
- How the progress of MyoPro3 and clinical trials will impact long-term revenue growth.
Related topics